Compare TOL & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOL | PODD |
|---|---|---|
| Founded | 1967 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7B | 17.0B |
| IPO Year | 1994 | 2007 |
| Metric | TOL | PODD |
|---|---|---|
| Price | $147.48 | $237.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 20 |
| Target Price | $163.44 | ★ $358.00 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 05-19-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 2.19 | ★ 3.48 |
| Revenue | ★ $7,143,258,000.00 | $2,708,100,000.00 |
| Revenue This Year | N/A | $24.33 |
| Revenue Next Year | $6.26 | $19.33 |
| P/E Ratio | ★ $68.32 | $69.44 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $86.67 | $230.08 |
| 52 Week High | $168.36 | $354.88 |
| Indicator | TOL | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 38.79 | 36.55 |
| Support Level | $133.98 | N/A |
| Resistance Level | $150.45 | $299.75 |
| Average True Range (ATR) | 4.85 | 8.38 |
| MACD | -1.92 | 0.50 |
| Stochastic Oscillator | 11.57 | 10.26 |
Toll Brothers Inc is the luxury homebuilder in the USA, operating in over 60 markets across 24 states. The Fort Washington, Pennsylvania-headquartered homebuilder caters to affluent first-time, move-up, active-adult, and second-homebuyers. Toll Brothers has shifted in recent years to a greater mix of speculative, or "quick move-in" homes. The homebuilder has also expanded its price points, with a greater emphasis on "affordable luxury. Traditional homebuilding accounts for the majority of Toll Brothers' earnings, but the firm also offers ancillary mortgage, title, insurance, and other services.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.